$1.84 Billion is the total value of BVF INC/IL's 62 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XNCR | XENCOR INC | $80,222,000 | +19.8% | 2,068,098 | 0.0% | 4.37% | +5.8% | |
| IDYA | IDEAYA BIOSCIENCES INC | $40,528,000 | -11.6% | 3,226,769 | 0.0% | 2.21% | -21.9% | |
| SNDX | SYNDAX PHARMACEUTICALS INC | $36,467,000 | -0.4% | 2,470,678 | 0.0% | 1.99% | -12.0% | |
| MTEM | MOLECULAR TEMPLATES INC | $23,468,000 | -20.8% | 2,149,057 | 0.0% | 1.28% | -30.0% | |
| GLYC | GLYCOMIMETICS INC | $22,240,000 | -18.3% | 7,244,262 | 0.0% | 1.21% | -27.9% | |
| INFI | INFINITY PHARMACEUTICALS INC | $20,390,000 | +29.3% | 17,426,968 | 0.0% | 1.11% | +14.2% | |
| CALT | CALLIDITAS THERAPEUTICS ABsponsored ads | $18,000,000 | +3.0% | 750,000 | 0.0% | 0.98% | -9.0% | |
| CTIC | CTI BIOPHARMA CORP | $14,899,000 | +85.4% | 6,929,690 | 0.0% | 0.81% | +63.5% | |
| PHAT | PHATHOM PHARMACEUTICALS INC | $11,811,000 | +11.4% | 322,098 | 0.0% | 0.64% | -1.7% | |
| GMDA | GAMIDA CELL LTD | $8,896,000 | -9.2% | 2,143,667 | 0.0% | 0.48% | -19.7% | |
| CFRX | CONTRAFECT CORP | $8,448,000 | -17.4% | 1,600,000 | 0.0% | 0.46% | -27.0% | |
| EVLO | EVELO BIOSCIENCES INC | $6,851,000 | +7.6% | 1,300,000 | 0.0% | 0.37% | -5.1% | |
| GLMD | GALMED PHARMACEUTICALS LTD | $6,353,000 | -26.2% | 1,799,694 | 0.0% | 0.35% | -34.7% | |
| CRIS | CURIS INC | $4,271,000 | -3.3% | 3,650,000 | 0.0% | 0.23% | -14.3% | |
| FWP | FORWARD PHARMA A/Ssponsord ads new | $4,033,000 | +1.6% | 647,299 | 0.0% | 0.22% | -10.2% | |
| ERYP | ERYTECH PHARMAsponsored adr | $3,906,000 | -25.8% | 625,000 | 0.0% | 0.21% | -34.3% | |
| BLRX | BIOLINERX LTDsponsored ads | $2,766,000 | -4.1% | 1,686,375 | 0.0% | 0.15% | -15.2% | |
| SBPH | SPRING BK PHARMACEUTICALS IN | $1,261,000 | -8.9% | 941,171 | 0.0% | 0.07% | -18.8% | |
| EXEL | EXELIXIS INC | $374,000 | +3.0% | 15,300 | 0.0% | 0.02% | -9.1% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.